Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Item 9 Labs (INLB) EBITDA Margin (2016 - 2023)

Item 9 Labs' EBITDA Margin history spans 12 years, with the latest figure at 57.45% for Q2 2023.

  • For Q2 2023, EBITDA Margin rose 1890.0% year-over-year to 57.45%; the TTM value through Jun 2023 reached 48.75%, up 10710.0%, while the annual FY2022 figure was 31.39%, 5594.0% up from the prior year.
  • EBITDA Margin reached 57.45% in Q2 2023 per INLB's latest filing, down from 22.89% in the prior quarter.
  • In the past five years, EBITDA Margin ranged from a high of 384.0% in Q3 2022 to a low of 627.09% in Q3 2019.
  • Average EBITDA Margin over 5 years is 36.63%, with a median of 37.0% recorded in 2021.
  • Peak YoY movement for EBITDA Margin: crashed -55572bps in 2019, then soared 82385bps in 2020.
  • A 5-year view of EBITDA Margin shows it stood at 76.32% in 2019, then soared by 86bps to 10.98% in 2020, then crashed by -204bps to 33.35% in 2021, then increased by 5bps to 31.68% in 2022, then plummeted by -81bps to 57.45% in 2023.
  • Per Business Quant, the three most recent readings for INLB's EBITDA Margin are 57.45% (Q2 2023), 22.89% (Q1 2023), and 31.68% (Q4 2022).